Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents

23 Aug 2010

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation
Share to DNA Repair Mechanisms

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 20729914
DOI: 10.1038/onc.2010.343

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agentsPMID 20729914Read ↗

CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.Semantic proximity Read ↗

Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents.Semantic proximity Read ↗

Chk1 Inhibitors for Novel Cancer TreatmentSemantic proximity Read ↗

Novel Checkpoint 1 InhibitorsSemantic proximity Read ↗

The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer CellsSemantic proximity Read ↗

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.Semantic proximity Read ↗

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.Semantic proximity Read ↗

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.Semantic proximity Read ↗

CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.Semantic proximity Read ↗

[CHEK1 expression and inhibitors in TP53 mutant cancer].Semantic proximity Read ↗

p21-activated kinases in human cancerSemantic proximity Read ↗

p53 is not directly relevant to the response of Polo-like kinase 1 inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.